Ocular Therapeutix, Inc. $OCUL Shares Sold by Northern Trust Corp

Northern Trust Corp cut its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,290,917 shares of the biopharmaceutical company’s stock after selling 23,954 shares during the quarter. Northern Trust Corp’s holdings in Ocular Therapeutix were worth $9,462,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Aptus Capital Advisors LLC boosted its position in Ocular Therapeutix by 1.9% during the first quarter. Aptus Capital Advisors LLC now owns 346,098 shares of the biopharmaceutical company’s stock worth $2,537,000 after acquiring an additional 6,348 shares during the last quarter. Brooklyn Investment Group boosted its position in Ocular Therapeutix by 151.5% during the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 3,155 shares during the last quarter. Algert Global LLC acquired a new stake in Ocular Therapeutix during the first quarter worth approximately $213,000. Nuveen LLC acquired a new stake in Ocular Therapeutix during the first quarter worth approximately $3,035,000. Finally, Banco Santander S.A. boosted its position in Ocular Therapeutix by 21.8% during the first quarter. Banco Santander S.A. now owns 184,048 shares of the biopharmaceutical company’s stock worth $1,349,000 after acquiring an additional 32,941 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OCUL. Scotiabank decreased their target price on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC raised their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, Ocular Therapeutix has a consensus rating of “Buy” and a consensus price target of $17.20.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,494 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $12.04, for a total value of $258,787.76. Following the completion of the sale, the insider owned 3,227,244 shares of the company’s stock, valued at approximately $38,856,017.76. The trade was a 0.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter Kaiser sold 3,011 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $12.04, for a total transaction of $36,252.44. Following the completion of the sale, the insider directly owned 204,093 shares of the company’s stock, valued at $2,457,279.72. The trade was a 1.45% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,519 shares of company stock valued at $367,865. Corporate insiders own 2.30% of the company’s stock.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL opened at $13.60 on Friday. The firm’s 50 day moving average is $11.68 and its two-hundred day moving average is $9.03. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $13.85. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The company has a market cap of $2.37 billion, a P/E ratio of -10.63 and a beta of 1.50.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The business had revenue of $13.46 million during the quarter, compared to analysts’ expectations of $13.12 million. During the same period in the prior year, the business posted ($0.26) EPS. The business’s revenue was down 17.7% on a year-over-year basis. Analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.